

115TH CONGRESS
2^D SESSION

H. R. 5418

IN THE SENATE OF THE UNITED STATES

MAY 22, 2018

Received; read twice and referred to the Committee on Veterans' Affairs

AN ACT

To direct the Secretary of Veterans Affairs to carry out the Medical Surgical Prime Vendor program using multiple prime vendors.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Veterans Affairs Med-
3 ical-Surgical Purchasing Stabilization Act”.

4 **SEC. 2. MEDICAL SURGICAL PRIME VENDOR PROGRAM.**

5 (a) VENDORS.—In procuring certain medical, sur-
6 gical, and dental supplies or laboratory supplies for med-
7 ical centers of the Department of Veterans Affairs, the
8 Secretary of Veterans Affairs shall carry out the Medical
9 Surgical Prime Vendor program, or successor program, in
10 a manner that—

11 (1) requires the Secretary to award contracts to
12 multiple regional prime vendors instead of a single
13 nationwide prime vendor; and

14 (2) prohibits a prime vendor from solely design-
15 ing the formulary of such supplies.

16 (b) CLINICALLY DRIVEN SOURCING.—

17 (1) EXPERTISE.—In carrying out the formulary
18 of supplies under the Medical Surgical Prime Vendor
19 program, or successor program, the Secretary shall
20 ensure that each employee of the Department of
21 Veterans Affairs who conducts formulary analyses or
22 makes decisions with respect to including items on
23 the formulary has medical expertise relevant to the
24 items for which the employee conducts such analyses
25 or makes such decisions.

1 (2) LISTS.—Not later than 30 days after the
2 date of the enactment of this Act, and quarterly
3 thereafter with respect to any updates, the Secretary
4 shall submit to the Committees on Veterans' Affairs
5 of the House of Representatives and the Senate a
6 list of each employee described in paragraph (1) and
7 the relevant medical expertise of the employee, listed
8 by the categories of items in the formulary described
9 in such paragraph.

Passed the House of Representatives May 21, 2018.

Attest:

KAREN L. HAAS,

Clerk.